IMFINZI ® (durvalumab), as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...

Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s IMFINZI ...

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

IMFINZI IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune ...

Imfinzi ® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery. News release. AstraZeneca. August 16, 2024.

These results will be presented today during a Presidential Symposium at the 2024 European Society for Medical Oncology Congress in Barcelona, Spain and simultaneously published in The New England ...

Imfinzi ® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer. News release. AstraZeneca. June 17, 2024.

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab). The approval is for the use of the drug ...

The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...